Figure 2From: PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues Metabolic stability of 177 Lu-DOTA-Lys-BN and 177 Lu-DOTA-PEG 5k -Lys-BN in human plasma. Back to article page